| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1104356813 |
| P356 | DOI | 10.1038/S41408-018-0078-3 |
| P932 | PMC publication ID | 5992153 |
| P698 | PubMed publication ID | 29880847 |
| P50 | author | Irene Bertozzi | Q83214275 |
| Elena Rossi | Q91801884 | ||
| Giorgina Specchia | Q38322931 | ||
| P2093 | author name string | Carlo Patrono | |
| Alessandro Rambaldi | |||
| Alessandro M Vannucchi | |||
| Guido Finazzi | |||
| Maria Luigia Randi | |||
| Francesco Rodeghiero | |||
| Marco Ruggeri | |||
| Nicola Vianelli | |||
| Bianca Rocca | |||
| Giovanna Petrucci | |||
| Giuseppe Carli | |||
| Alessandra Iurlo | |||
| Alberto Tosetto | |||
| Linda Turnu | |||
| Viviana Cavalca | |||
| Valerio De Stefano | |||
| Alfredo Dragani | |||
| Daniele Cattaneo | |||
| Silvia Betti | |||
| Francesca Palandri | |||
| Chiara Paoli | |||
| Elena Elli | |||
| Monica Carpenedo | |||
| Eloise Beggiato | |||
| Alessandra Ricco | |||
| Giuseppe Lanzarone | |||
| Andrea Timillero | |||
| Denise Soldati | |||
| Paola Ranalli | |||
| Laura Lissandrini | |||
| P2860 | cites work | ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary | Q22241786 |
| The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes | Q22299206 | ||
| Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials | Q24645391 | ||
| The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia | Q27853375 | ||
| Efficacy and safety of low-dose aspirin in polycythemia vera | Q28166691 | ||
| Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events | Q28192726 | ||
| Increased thromboxane biosynthesis in essential thrombocythemia. | Q51036158 | ||
| On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens. | Q51070680 | ||
| In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia. | Q51287516 | ||
| Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. | Q51453304 | ||
| Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement. | Q53213155 | ||
| Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments | Q61050105 | ||
| Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects | Q71172266 | ||
| Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis | Q77768132 | ||
| Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients | Q81670366 | ||
| Twice daily aspirin to improve biological aspirin efficacy in patients with essential thrombocythemia | Q82117391 | ||
| The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes | Q83797596 | ||
| Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia | Q84317819 | ||
| Platelet progenitors: the hidden drug target | Q85696622 | ||
| Low-dose aspirin for the prevention of atherothrombosis | Q28193680 | ||
| Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease | Q28194421 | ||
| Estimated rate of thromboxane secretion into the circulation of normal humans | Q34521662 | ||
| Protease-activated receptor signaling in platelets activates cytosolic phospholipase A2α differently for cyclooxygenase-1 and 12-lipoxygenase catalysis | Q34560219 | ||
| Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects | Q36984424 | ||
| Platelet activation and atherothrombosis | Q37031278 | ||
| Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization | Q37649227 | ||
| Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. | Q37900078 | ||
| Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. | Q37934479 | ||
| Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union | Q38174215 | ||
| How common are myeloproliferative neoplasms? A systematic review and meta-analysis. | Q38223791 | ||
| Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study. | Q38471154 | ||
| Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. | Q38695989 | ||
| Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway | Q39513246 | ||
| Clinical pharmacology of platelet cyclooxygenase inhibition | Q39849855 | ||
| Reliability, validity, and responsiveness of severity of dyspepsia assessment (SODA) in a randomized clinical trial of a COX-2-specific inhibitor and traditional NSAID therapy | Q40664359 | ||
| Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man. | Q40682170 | ||
| Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. | Q40756300 | ||
| Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011. | Q40945373 | ||
| Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study | Q41190830 | ||
| Aspirin response: Differences in serum thromboxane B2 levels between clinical studies. | Q41485945 | ||
| European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke | Q42551725 | ||
| The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. | Q43249093 | ||
| Platelet activation and inhibition in polycythemia vera and essential thrombocythemia | Q44117506 | ||
| Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". | Q46114498 | ||
| Essential thrombocythemia treatment algorithm 2018. | Q47565721 | ||
| In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes. | Q48119354 | ||
| The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients | Q48680927 | ||
| Influence of pre-analytical time and temperature conditions on serum thromboxane B2 levels | Q50087889 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 6 | |
| P921 | main subject | aspirin | Q18216 |
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 49 | |
| P577 | publication date | 2018-06-01 | |
| P1433 | published in | Blood Cancer Journal | Q2464036 |
| P1476 | title | The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting | |
| P478 | volume | 8 |
| Q92509180 | Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper |
| Q64272828 | Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome |
Search more.